For people living with type 1 diabetes, new treatments may be finally on the horizon.
Paresh Dandona, MD, PhD, SUNY Distinguished Professor of
medicine and chief of
endocrinology, diabetes and metabolism, describes how the University at Buffalo Endocrinology Research Center is helping to revolutionize the treatment of this condition. He explains why two non-insulin medications currently used in type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists, are among the most promising new therapies. “The hope is that non-insulin therapies will soon be approved for type 1 diabetes. By unlocking the potential of these therapies, we can do more than manage blood glucose levels – we can improve people’s lives,” writes Dandona.